Baxter Introduced New Injectable Pharmaceuticals to US Market
On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential demands in therapeutic domains like anti-hypertensive and anti-infective drugs.
Among the new products is a ready-to-use injection of norepinephrine bitartrate in 5% Dextrose, which is now available in three strengths—including a brand-new 16 mg/250 mL option—for severe, acute hypotension. This is the first and only ready-to-use formulation of its sort, accor...